|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (5Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
Juniper Pharmaceuticals (JNP) delivered earnings and revenue surprises of -450.00% and -6.07%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Boston-based company said it had a loss of 14 cents per share. The pharmaceutical company posted revenue of $15.3 million in the period. Juniper Pharmaceuticals shares have more than doubled since ...
Under the terms of the transaction, Juniper shareholders will receive only $11.50 in cash for each share of Juniper stock they own. The investigation concerns whether the Board of Juniper breached their fiduciary duties to shareholders and whether Catalent is underpaying for the Company.
Juniper Pharmaceuticals, Inc. (JNP) inks a deal with Catalent, Inc. Per the deal, Catalent will acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash.
NEW YORK, NY / ACCESSWIRE / July 4, 2018 / Health stocks Anavex Life Sciences Corp. and Juniper Pharmaceuticals were both exploding in Tuesday trading on positive developments. Anavex announced it has ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 2) Acer Therapeutics Inc (NASDAQ: ACER ) Arrowhead Pharmaceuticals ...
U.S. drug contract manufacturer Catalent Inc said on Tuesday it will buy Juniper Pharmaceuticals Inc for $11.50 per share in cash. The offer price represents a premium of about 32 percent to Juniper Pharmaceuticals' closing price of $8.70 on Monday and values the company at about $127.7 million, according to Thomson Reuters calculations. Catalent has a market value of about $5.58 billion, according to Thomson Reuters data.
Juniper Pharmaceuticals Inc (NASDAQ:JNP) generated a below-average return on equity of 0.30% in the past 12 months, while its industry returned 12.26%. Though JNP’s recent performance is underwhelming, it isRead More...
Investors are always looking for growth in small-cap stocks like Juniper Pharmaceuticals Inc (NASDAQ:JNP), with a market cap of US$91.03M. However, an important fact which most ignore is: how financiallyRead More...
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Juniper Pharmaceuticals Inc’s (NASDAQ:JNP) track record on a high level, toRead More...
Juniper Pharmaceuticals Inc (NASDAQ:JNP), a pharmaceuticals company based in United States, led the NasdaqGS gainers with a relatively large price hike in the past couple of weeks. As a smallRead More...
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Juniper Pharmaceuticals, Inc. (NASDAQ: JNP ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018 at 8:30 AM Eastern ...